Dental Care Clinics in Blythe, CA Accepting Medicare
4 Dental Care Clinics found. Showing 1 - 4
 Epifania V Nicolas Dds Inc. Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 E Hobsonway, Blythe, CA 92225 Phone: 760-922-2300 Fax: 760-922-2277 |
Epifania V Nicolas Dds Inc Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 E Hobsonway, Blythe, CA 92225 Phone: 760-922-2300 |
Smile Bright Dental Care Inc Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 E Hobsonway, Blythe, CA 92225 Phone: 760-922-2300 |
Nicolas Dental Corporation Dentist Medicare: Not Enrolled in Medicare Practice Location: 301 E Hobsonway, Blythe, CA 92225 Phone: 760-922-2300 Fax: 760-922-2277 |
News Archive
IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis
Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.
Lawmakers renew demands for public option in health bill
Senate and House Democrats are renewing their calls for a strong government-run public option in their respective chambers.
African Americans with prostate cancer experience longer treatment delays after diagnosis
Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.
› Verified 6 days ago